- Home
- REGN
as 01-17-2025 4:00pm EST
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases; Praluent for LDL cholesterol lowering; Dupixent in immunology; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and CRISPR-based gene editing (Intellia).
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | TARRYTOWN |
| Market Cap: | 110.0B | IPO Year: | 1991 |
| Target Price: | $1024.28 | AVG Volume (30 days): | 857.0K |
| Analyst Decision: | Buy | Number of Analysts: | 25 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 40.43 | EPS Growth: | 15.31 |
| 52 Week Low/High: | $666.25 - $1211.20 | Next Earning Date: | 02-04-2025 |
| Revenue: | $13,847,100,000 | Revenue Growth: | 5.72% |
| Revenue Growth (this year): | 10.24% | Revenue Growth (next year): | 4.30% |
Stock Insider Trading Activity of Regeneron Pharmaceuticals Inc. (REGN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| McCourt Marion | REGN | EVP Commercial | Nov 1 '24 | Sell | $844.61 | 1,000 | $844,610.00 | 12,931 |
Latest Regeneron Pharmaceuticals Inc. News
REGN Breaking Stock News: Dive into REGN Ticker-Specific Updates for Smart Investing
Insider Monkey
2 days ago
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘This Company Has Never Lost Its Ability To Develop New Medicines’
Zacks
4 days ago
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
Zacks
4 days ago
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
Fortune
4 days ago
Pharma giant Regeneron is spending $119.5M on the world’s largest, most diverse genetic database using DNA from patient volunteers
Zacks
4 days ago
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
Investing.com
4 days ago
UBS cuts rating on Regeneron stock amid Eylea uncertainty
MT Newswires
5 days ago
UBS Downgrades Regeneron Pharmaceuticals to Neutral From Buy, Cuts Price Target to $738 From $1,130
Insider Monkey
5 days ago
Jim Cramer on Regeneron Pharmaceuticals, Inc. (REGN): ‘Stock That Seems To Have Disappointed People. Bizarre’
Compare REGN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "REGN Regeneron Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.